Recipharm and Adroit Science Collaborate to Expand Development Services
Adroit Science AB will support Recipharm’s pharmaceutical development with solid-state characterization services.
Recipharm AB and Adroit Science AB have formed a new strategic collaboration to expand their service offering. Adroit Science AB will support Recipharm’s pharmaceutical development with solid-state characterization services. The combination of both companies’ expertise in formulation development, API development, chemical analysis, and solid-state characterization, will improve speed and reduce development costs, while improving quality.
Carl-Johan Spak, executive vice-president, Development & Technology at Recipharm, commented in a press release that the addition of development services from Adroit provides a competitive offering that will help customers to progress their projects more efficiently, including complete development from molecule to product. Adroit Science AB has established itself as a provider of solid-state characterization services in Northern Europe.
According to Hans Gredeby, CEO of Adroit Science AB, Adroit Science and Recipharm have already cooperated in a number of projects and this partnership marks the next step in the mutual development of both companies’ relationship.
Source: Recipharm
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
